Consumer Perceptions of Health Claims in Vape Shops

项目总结/摘要 2016年5月，美国食品药品监督管理局（FDA）发布了一项最终规则， 尼古丁输送系统（ENDS）和其他符合法定定义的产品 烟草制品在其管辖范围内联邦法律明确禁止五类标签 烟草产品广告包括：（1）虚假和/或误导;（2）FDA批准的或 FDA认可，未经FDA批准;（3）改良风险烟草产品，未经FDA批准 批准此外，ENDS不能作为（4）戒烟或 (5)其他治疗目的，未经FDA药物中心事先批准 评估和研究（CDER）。虽然这些类型的ENDS索赔已经被 由于在网上和印刷媒体上都有记录，因此很难识别被禁止的声明， 往往是含蓄的。FDA的任务是考虑消费者对此类声明的看法 当确定它们是否被禁止时;然而，文献中存在重大空白 关于消费者对健康声明的看法。此外，没有进行任何研究 在电子烟商店中进行的广告索赔，这是ENDS增长最快的部分 零售商这项研究将建立在一个试点赠款，开发的方法， 使用可穿戴成像技术在vape商店中记录ENDS索赔。在 在拟议的研究中，我们将使用这种方法来进行额外的一波数据 收集来记录电子烟商店的索赔。飞行员和新浪潮的声明 收集的数据将合并起来，以建立一个未经证实的索赔的全面清单， 在一项调查中使用，调查消费者对它们的看法。这将是第一个这样的 以评估消费者如何理解零售商提出的这些真实世界的ENDS健康声明。在 本研究的结论是，我们将开发出强大的方法来捕捉索赔 在ENDS零售环境中;扩大了ENDS索赔类型的知识， 并制定了评估消费者对这些产品的看法的措施。 所有这些都将有助于FDA确定这些索赔是否属于 禁止的类别之一。这个重点项目，由一个新的研究人员与一个 国家认可的合作者团队，将为未来更大规模的研究奠定基础， 将增加有关ENDS的证据，并直接告知 FDA对禁止的广告声明进行识别和分类。

PROJECT SUMMARY/ABSTRACT In May 2016, the Food and Drug Administration (FDA) issued a Final Rule, bringing electronic nicotine delivery systems (ENDS) and other products that meet a statutory definition of a tobacco product under its authority. Federal law explicitly prohibits five categories of labelling and advertising for tobacco products including: (1) false and/or misleading; (2) FDA-approved or FDA-endorsed, without FDA approval; and (3) modified risk tobacco product, without FDA approval. Additionally, ENDS cannot be marketed as a product for (4) smoking cessation or for (5) other therapeutic purposes, without prior approval from the FDA's Center for Drug Evaluation and Research (CDER). Although these types of ENDS claims have been documented online and in print media, it can be difficult to identify prohibited claims as they are often implicit. The FDA has been tasked with considering consumer perceptions of such claims when determining if they are prohibited; however, there is a significant gap in the literature regarding consumer perceptions of health claims. Additionally, no research has been conducted on advertising claims made in vape shops, which are the fastest growing segment of ENDS retailers. This study will build upon a pilot grant that developed the methodology to photographically document ENDS claims in vape shops using wearable imaging technology. In the proposed study, we will use this methodology to conduct an additional wave of data collection to document claims in vape shops. The claims from both the pilot and the new wave of data collection will be combined to create a comprehensive list of unsubstantiated claims for use in a survey, which will investigate consumer perceptions of them. It will be the first of its kind to assess how consumers interpret these real-world ENDS health claims made by retailers. At the conclusion of this study, we will have developed robust methodologies for capturing claims in the ENDS retail environment; expanded the knowledge of the types of ENDS claims being made to consumers; and developed measures for assessing consumer perceptions of those claims, all of which will aid the FDA in making determinations of whether such claims fall into one of their prohibited categories. This focused project, led by a New Investigator working with a nationally recognized team of collaborators, will lay the groundwork for future, larger studies that will increase the body of evidence regarding ENDS and directly inform the process in which the FDA identifies and classifies prohibited advertising claims.